Rac1-IN-2

Rac1-IN-2 (compound #6) (10 μM; 2 h) inhibits Rac1 activity in CD18/HPAF cells^[1].
Rac1-IN-2 (1-50 μM; 2 h) inhibits EGF-induced Rac1 activation in CD18/HPAF cells with an EC₅₀ of 22.4 μM^[1].
Rac1-IN-2 (50 μM; 2 h) selectively inhibits Rac1 activity in CD18/HPAF cells without inhibiting Cdc42 or RhoA^[1].
Rac1-IN-2 (25 μM; 24-120 h) inhibits the proliferation of Capan1 and CD18/HPAF cells^[1].
Rac1-IN-2 (50 μM; 24-48 h) inhibits the migration of Capan1 and CD18/HPAF cells, with maximal wound closure inhibition of approximately 60% and 40%, respectively^[1].
Rac1-IN-2 (50 μM; 1 h pre-incubation; 24 h migration) inhibits transwell migration of Capan1 and CD18/HPAF cells^[1].
Rac1-IN-2 (7 days) reduces clonogenic survival of Capan1 cells, with little effect on HPNE normal pancreatic ductal cells^[1].
Rac1-IN-2 (1.6-100 μM; 7 days) reduces the viability of AsPC-1, Capan1, and CD18/HPAF cells with EC₅₀ values of 14.7, 24.2, and 23.5 μM, respectively^[1].
Rac1-IN-2 (0.001-100 μM; 1 h) disrupts Rac1-PAK1 complex formation with an IC₅₀ of 88 nM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.